Target with-in target

Aiming to break therapeutic mediocrity

Mohammed Abdul Hannan Hazari
Professor, Department of Physiology,
Deccan College of Medical Sciences,
DMRL 'X' Road, Kanchanbagh, Hyderabad-500058,
Telangana, India.

Article History
Submitted: 2017-08-21
Accepted: 2017-08-22
Online: 2018-03-26
Print: 2018-03-31

Conflict of interest: None declared.

How to cite
Hazari MA. Target with-in target. Ann Med Physiol. 2018 Jan-Mar; 2(1):1-2. doi: 10.23921/amp.2018v2i1.275951

Scan QR Code

Full text

Molecular targets (MT) are intra-cellular structures, ranging from proteins to DNA and RNA that are potential entities for pharmacological action. With advancements in different sub-cellular domains viz. glycomics, lipidomics, proteomics, genomics, transcriptomics, metabolomics, etc it has made possible identification of specific target molecules that are either up-regulated or down-regulated during physiological processes and in various disordered / diseased states.

MT can be visualized by means of molecular imaging which maps the functions at cellular and molecular level in contrast to conventional diagnostic imaging which render good details of physical structure [1]. Molecular imaging encompasses nuclear medicine, radio-pharmacology and radio-pharmaceuticals which largely make use of small quantities of radio-active isotopes. These procedures are minimally invasive, safe and cause little pain [2]. These in-vivo techniques make use of existing imaging modalities like magnetic resonance imaging (MRI), positron emission tomography (PET), etc coupled with biomarker probes which chemically interact with extra- and intra-cellular milieu bringing about a change in image according to the molecular alterations in the desired area. The images are captured in real-time with highly sophisticated microscopy and nanoscopy procedures like atomic force microscopy (AFM), total internal reflection fluorescence (TIRF) microscopy and stimulated emission depletion (STED) nanoscopy. Furthering the scope of molecular imaging was the development of mass-spectrometry based matrix-assisted laser desorption/ionization (MALDI) technique which allows quantitative analysis [3].

Though small molecules and protein therapeutics are well established agents in current pharmaco-therapeutics, their target range is limited to only one-tenth of the cell membrane surface or hydrophobic protein facade. With these short-comings, research efforts are directed in discovering next generation therapeutic approaches. Firstly, exploration of entities that promote the active endosomal uptake and release of molecules which are not lipid soluble like polypeptides, proteins and nucleic acids. Secondly, identification of molecules that enters the cell by passive diffusion, facilitated diffusion or active transport so as to reach the intracellular molecular targets [4].

The targets for the pharmacological agents can be categorized under 9 headings (Table 1).

Table 1: Categories of pharmaco-therapeutic targets [5]
Category Site of action Mechanism Example
Various physicochemical mechanisms Extra-cellular Acid binding Aluminium hydroxide
Targets of monoclonal antibodies Cell surface Immunoglobulin E (IgE) Omalizumab
Transport proteins Cell surface Inhibitors of Na+/K+ ATPase Digoxin
Ionic channels Cell surface Inhibitor of Epithelial Na+ channels (ENaC) Amiloride
Receptors Cell surface Agonist of vasopressin receptor Vasopressin
Cytoplasmic Glucocorticoid receptors Glucocorticoids
Intra-nuclear Thyroid hormone receptors Thyroxine
Enzymes Cytoplasmic Cyclooxygenase-2 (COX-2) inhibitor Acetaminophen
Substrates, metabolites, proteins Cytoplasmic Asparagine Asparaginase
DNA/RNA and ribosomes Cytoplasmic and Intra-nuclear Interaction with r-RNA Aminoglycosides
Unknown mechanism of action - - Ambroxol

Biotherapeutics, production of therapeutic materials using biological means, encompass techniques like recombinant DNA technology, genetic engineering, etc. Noteworthy progress has been made in the field of cancer therapeutics with identification/development of molecules capable of generating extra-cellular or intra-cellular death signals which plunges the malignant cells to undergo apoptosis. One approach is development of tumor targeting antibody fragments genetically fused to a cytotoxic protein payload called Targeted Protein Therapeutics (TPTs) [6]. Other approaches being worked on are intra-cellular antibodies (intrabodies) [7] and peptide aptamers [8]. These developments are taking the therapeutics way forward, albeit rather slowly. Despite the fact that in-vitro studies are promising, some of the challenges still elude their application in in-vivo or real situation and cause high attrition in drug discovery. Few critical elements in successful drug development and designing are adequate target exposure, bio-availability (both extra-cellular and intra-cellular) and ideal route of delivery. Recently, a technique was developed to quantify the intra-cellular concentration of drug and hence its availability to bind to molecular target which translates into pharmacological effect [9].

Earlier, the physiological basis of medicine was to target the cells, but of late the efforts are directed towards targeting sub-cellular structures. So, this is what is meant by 'Target with-in target: Aiming to break therapeutic mediocrity'.


  1. Bremer C. Molecular targets. In: Baert AL (ed) Encyclopedia of Diagnostic Imaging. New York: Springer Berlin Heidelberg, pp.1154-55, 2008.
  2. Society of Nuclear Medicine and Molecular Imaging. What are molecular imaging and nuclear medicine? Available from: [Last accessed August 16, 2017]
  3. Molecular imaging. Available from: (Last accessed August 16, 2017)
  4. Verdine GL, Hilinski GJ. Stapled peptides for intracellular drug targets. Methods Enzymol. 2012; 503:3-33. [Pubmed] [Crossref]
  5. Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct; 5(10):821-34. [Pubmed] [Crossref]
  6. Eleven Biotherapeutics. Vicinium™ (VB4-845): Recombinant fusion protein in clinical development for the treatment of high-grade non-muscle invasive bladder cancer. Available from: (Last accessed August 21, 2017)
  7. Cardinale A, Biocca S. The potential of intracellular antibodies for therapeutic targeting of protein-misfolding diseases. Trends Mol Med. 2008 Sep; 14(9):373-80. [Pubmed] [Crossref]
  8. Reverdatto S, Burz DS, Shekhtman A. Peptide aptamers: development and applications. Curr Top Med Chem. 2015; 15(12):1082-101. [Pubmed] [Crossref]
  9. Mateus A, Gordon LJ, Wayne GJ, Almqvist H, Axelsson H, Seashore-Ludlow B, Treyer A, Matsson P, Lundbäck T, West A, Hann MM, Artursson P. Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery. Proc Natl Acad Sci U S A. 2017 Jul 25; 114(30):E6231-E6239. [Pubmed] [Crossref]